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Moreover, cerebral Aβ deposition is increased in human epilepsy 
(Mackenzie and Miller, 1994) and seizures are increased in human 
AD (Palop et al., 2007).
Increased cognitive activity is also able to increase Aβ secretion, 
since recovery of cognitive function after brain injury correlates 
with increased levels of extracellular Aβ in human brain (Brody 
et al., 2008). Levels of Aβ in the interstitial ﬂ  uid have been shown 
to follow the circadian rhythm, being elevated when awake and 
reduced when asleep (Kang et al., 2009). These observations sup-
port that Aβ secretion could be a physiologic event occurring with 
normal brain activity. With activity-induced secretion, the concen-
tration of extracellular Aβ remains in the picomolar range in vitro 
as well as in vivo (Cirrito et al., 2003; Trinchese et al., 2004b). It 
can be hypothesized that at this low concentration extracellular Aβ 
might be nontoxic. Indeed, recent studies reported that picomolar 
concentrations of Aβ enhanced synaptic plasticity and memory 
(Puzzo et al., 2008; Garcia-Osta and Alberini, 2009).
Another set of studies supports the idea that cognitive activity may 
be protective against AD. Higher educational level or involvement in 
mentally stimulating activities correlated with a lower probability 
of developing AD (Stern, 2006). Experiments on environmental 
enrichment in AD transgenic mice demonstrated reduced plaque 
deposition and up-regulation of genes involved in memory forma-
tion and Aβ degradation (Lazarov et al., 2005). Moreover, recent 
cell biological studies provided evidence that synaptic activation 
reduces levels of intraneuronal Aβ and protects synapses in models 
of AD, despite a concomitant increase in Aβ secretion (Tampellini 
et al., 2009). Next to the well known presence of extracellular Aβ 
as plaques, AD pathology also includes a pool of Aβ accumulating 
within neurons (Gouras et al., 2000; D’Andrea et al., 2001; Gyure 
et al., 2001; Wirths et al., 2001; Mori et al., 2002; Oddo et al., 2003; 
Cataldo et al., 2004), which is   increasingly   considered to play a 
Synapses are considered the earliest site of pathology, and synaptic 
loss is the best pathological correlate of cognitive impairment in 
Alzheimer’s disease (AD) (Hamos et al., 1989; DeKosky and Scheff, 
1990; Terry et al., 1991; Selkoe, 2002; Coleman and Yao, 2003). 
Toxic effects of extracellular β-amyloid (Aβ) on synapses have been 
known for many years. Synapses and neurites are also frequently 
damaged near Aβ plaques (Dong et al., 2007; Meyer-Luehmann 
et al., 2009). The ﬁ  rst direct association between Aβ peptide and 
synapse pathologies in the brain was provided by immunoelectron 
microscopy (IEM); this showed that aberrant Aβ42 accumulation 
within distal neurites and synapses was directly associated with 
pathology (Takahashi et al., 2002). Emerging studies have provided 
very interesting evidence that synaptic activity modulates Aβ home-
ostasis. Increased synaptic activation enhanced, while inhibition 
reduced, secretion of Aβ in cultured hippocampal slices and mouse 
brains (Kamenetz et al., 2003; Cirrito et al., 2005; Cirrito et al., 
2008). These were important discoveries and appeared to ﬁ  t the sce-
nario that brain areas with the highest synaptic activity, including 
hippocampus and entorhinal cortex, are among the most vulner-
able to early AD pathology (Buckner et al., 2005). Extracellular Aβ 
is known to reduce synaptic plasticity, and alter synaptic function, 
structure and protein levels in AD model systems (Selkoe, 2002; 
Trinchese et al., 2004a; Almeida et al., 2005; Snyder et al., 2005; 
Hsieh et al., 2006; Shankar et al., 2008; Deshpande et al., 2009). 
Therefore, increased secretion of Aβ induced by synaptic activ-
ity could lead to damage and loss of synapses and to progressive 
accumulation of extracellular Aβ into amyloid plaques, which are 
important hallmarks of AD. From this point of view, synaptic activ-
ity could be detrimental and contribute to AD pathogenesis. In fact, 
aberrant hyperexcitability is present in brains of AD transgenic 
mice (Palop et al., 2007; Busche et al., 2008), which could increase 
activity-induced release of Aβ and thereby aggravate pathology. 
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critical role in the disease (Gouras et al., 2005; LaFerla et al., 2007; 
Bayer and Wirths, 2010). Accumulation and oligomerization of 
Aβ42, the most pathologic Aβ isoform, occurs progressively within 
distal neurites and synaptic compartments, and is directly asso-
ciated with subcellular pathology (Takahashi et al., 2002, 2004) 
and with alterations of synaptic proteins (Almeida et al., 2005). 
Furthermore, intraneuronal Aβ accumulation is associated with 
the pre-plaque onset of physiological and behavioral abnormali-
ties in AD transgenic models (Oddo et al., 2003; Echeverria et al., 
2004; Billings et al., 2005; Cruz et al., 2006; Knobloch et al., 2007; 
Lord et al., 2009). Clearance of intraneuronal Aβ by treatment 
with Aβ antibodies protected synapses (Tampellini et al., 2007) 
and correlated with memory improvement (Billings et al., 2005). 
Overall, cumulative evidence support a scenario where progres-
sive accumulation of intraneuronal Aβ42 becomes extracellular 
not by secretion but rather following degeneration of neurites and 
synapses. Release of this intraneuronal Aβ42 into the extracellular 
space may then result in an abnormally high concentration of extra-
cellular Aβ42, potentially leading to toxic spread of Aβ pathology to 
surrounding synapses (Figure 1). Given the emerging evidence of 
declining extracellular Aβ42 levels in cerebrospinal ﬂ  uid (CSF) in 
patients as the earliest harbinger for the subsequent development 
of AD (Fagan et al., 2009), one can now even hypothesize that AD 
is characterized by decreased Aβ42 secretion as Aβ42 accumulates 
inside neurons.
It is important to note that the extra- and intracellular pools 
of Aβ are related, although their relationship is complex and 
they can inﬂ  uence each other (Yang et al., 1999; Oddo et al., 
2006; Tampellini et al., 2009). Intraneuronal Aβ accumulation 
begins before plaques (Gouras et al., 2000; Wirths et al., 2001; 
Mori et al., 2002; Oddo et al., 2003), and, after clearance by Aβ 
immunotherapy, reappears prior to plaques (Oddo et al., 2004). 
How speciﬁ  cally extracellular Aβ is toxic to neurons and synapses 
remains poorly understood, but appears to occur via APP and 
potentially intraneuronal Aβ. Addition of extracellular Aβ1–42 
markedly increased intracellular Aβ (Yang et al., 1999; Tampellini 
et al., 2009). The role and extent of Aβ internalization from the 
extracellular space remain less clear (Yang et al., 1999; Saavedra 
et al., 2007; Kandimalla et al., 2009). Yang et al. (1999) showed 
minimal internalization of labeled Aβ1–42, whereas adding of 
unlabeled Aβ1–42 lead to a marked up- regulation of newly gener-
ated intracellular Aβ42. Extracellular Aβ1–42 was shown to induce 
cell death in wild type neurons but not in neurons lacking APP 
(Lorenzo et al., 2000) or in cells where the NPXY motif of APP 
was mutated (Shaked et al., 2006). Moreover, extracellular Aβ1–42 
is unable to reduce levels of synaptic proteins in APP knockout 
neurons or when it is applied together with a γ-secretase inhibitor 
(Tampellini et al., 2009). Overall, these data suggest that extracel-
lular Aβ1–42 synapto-toxicity requires γ-secretase cleavage of APP 
and also intraneuronal Aβ42 accumulation.
The precise molecular and cellular mechanism(s) whereby syn-
aptic activity modulates Aβ and then Aβ ﬁ  rst alters synapses are 
of major interest. The reduction of intracellular Aβ with synaptic 
activation is partially due to secretion of intracellular Aβ to the 
extracellular space (Tampellini et al., 2009). Aβ degradation is also 
involved in the reduction of the intraneuronal pool during activity. 
Synaptic activity failed to reduce the intraneuronal pool of Aβ42 in 
the presence of the neprilysin inhibitor thiorphan or in neprilysin 
knockout neurons. These data implicate neprilysin in the degrada-
tion of the most disease-linked Aβ isoform with activity. In contrast, 
levels of intraneuronal Aβ40 were still decreased, although to a 
lesser extent, with thiorphan treatment or in neprilysin knockout 
neurons, during synaptic activity (Tampellini et al., 2009). This 
might be explained by Aβ40 being more soluble and more abun-
dantly secreted than Aβ42 (Kamenetz et al., 2003). The reduction of 
intraneuronal Aβ with synaptic activity, which correlated with syn-
aptic improvement, supports the hypothesis that synaptic activity 
may also be protective in AD pathogenesis. Currently, AD patients 
are encouraged to increase their mental and social activities. We 
hypothesize that under physiological conditions of synaptic activity 
both extra- and intracellular pools of Aβ are efﬁ  ciently cleared, but 
then with aging and other AD risk factors (e.g. apolipoprotein Eε4), 
Aβ clearance mechanisms become impaired. It is of considerable 
interest that levels of neprilysin have been reported to decrease 
with aging (Iwata et al., 2002; Apelt et al., 2003). Because nepri-
FIGURE 1 | (A) Accumulation of intraneuronal Aβ42 at early stages of AD 
occurs progressively in a synapse (left) and is associated with pathological 
alterations compared to a normal synapse (right). (B) Intraneuronal Aβ42 is 
released in the extracellular space following degeneration of the synapse (left). 
Release of intraneuronal Aβ42 into the extracellular space may contribute to 
the toxic spread of Aβ pathology to a nearby synapse (right).Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 13  |  3
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lysin localizes to synapses (Fukami et al., 2002), its age-dependent 
decline could explain the progressive synaptic accumulation of 
Aβ42 (Takahashi et al., 2002, 2004, 2008).
With synaptic activation, APP is anterogradely transported to 
synapses, followed by internalization and amyloidogenic process-
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aptic activity on transport in neurites of protein cargoes is not 
uniform (Perestenko and Henley, 2003; Bingol and Schuman, 
2006; Cai et al., 2007; Kang et al., 2008). The synaptic activity-
dependent increase of APP anterograde transport and β-cleavage 
support that Aβ production is locally enhanced at activated syn-
apses (Cirrito et al., 2008; Tampellini et al., 2009). How Aβ starts to 
accumulate at synapses and contributes to pathogenesis remains 
unclear. The role of aging should not be underestimated in pro-
moting AD pathogenesis. Mitochondrial dysfunction and oxida-
tive stress, as well as reduced cellular degradation, appear to be 
important contributors to the neurobiology of aging. In fact, it 
was reported that elevated oxidative stress promoted Aβ pathol-
ogy in AD transgenic mice (Li et al., 2004). On the other hand, 
once Aβ accumulation begins with aging, it is unclear how Aβ then 
contributes to progression of synaptic dysfunction. Cumulative 
data over the past two decades support that APP is trafﬁ  cked via 
the Golgi apparatus to the plasma membrane where α-secretase 
cleavage can occur and thereby preclude Aβ formation. An addi-
tional pool of APP is re-internalized from the plasma membrane 
and then processed to Aβ peptides in endosomes (Rajendran 
et al., 2008; Thinakaran and Koo, 2008), followed by secretion of 
predominantly Aβ40 peptides. Evidence supports that relatively 
higher amounts of the more hydrophobic, aggregation-prone and 
AD-linked Aβ42 is retained within endosomes. It is this pool Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 13  |  4
Tampellini and Gouras  Aβ and synapses in AD
 isoxazole propionic acid receptor sub-
units in hippocampal neurons. J. Biol. 
Chem. 278, 43525–43532.
Puzzo, D., Privitera, L., Leznik, E., Fa, 
M., Staniszewski, A., Palmeri, A., and 
Arancio, O. (2008). Picomolar amy-
loid-beta positively modulates synaptic 
plasticity and memory in hippocam-
pus. J. Neurosci. 28, 14537–14545.
Rajendran, L., Schneider, A., Schlechtingen, 
G., Weidlich, S., Ries, J., Braxmeier, T., 
Schwille, P., Schulz, J. B., Schroeder, C., 
Simons, M., Jennings, G., Knolker, H. 
J., and Simons, K. (2008). Efficient 
inhibition of the Alzheimer’s disease 
beta-secretase by membrane targeting. 
Science 320, 520–523.
Reddy, P. H. (2009). Amyloid beta, mito-
chondrial structural and functional 
dynamics in Alzheimer’s disease. Exp. 
Neurol. 218, 286–292.
Saavedra, L., Mohamed, A., Ma, V., 
Kar, S., and de Chaves, E. P. (2007). 
Internalization of beta-amyloid pep-
tide by primary neurons in the absence 
of apolipoprotein E. J. Biol. Chem. 282, 
35722–35732.
Selkoe, D. J. (2002). Alzheimer’s disease is a 
synaptic failure. Science 298, 789–791.
Shaked, G. M., Kummer, M. P., Lu, D. C., 
Galvan, V., Bredesen, D. E., and Koo, 
E. H. (2006). Abeta induces cell death 
by direct interaction with its cognate 
extracellular domain on APP (APP 
597-624). FASEB J. 20, 1254–1256.
Shankar, G. M., Li, S., Mehta, T. H., Garcia-
Munoz, A., Shepardson, N. E., Smith, 
I., Brett, F. M., Farrell, M. A., Rowan, M. 
J., Lemere, C. A., Regan, C. M., Walsh, 
D. M., Sabatini, B. L., and Selkoe, D. 
J. (2008). Amyloid-beta protein dim-
ers isolated directly from Alzheimer’s 
brains impair synaptic plasticity and 
memory. Nat. Med. 14, 837–842.
Snyder, E. M., Nong, Y., Almeida, C. G., 
Paul, S., Moran, T., Choi, E. Y., Nairn, 
A. C., Salter, M. W., Lombroso, P. J., 
Gouras, G. K., and Greengard, P. 
(2005). Regulation of NMDA recep-
tor trafﬁ  cking by amyloid-beta. Nat. 
Neurosci. 8, 1051–1058.
Stern, Y. (2006). Cognitive reserve and 
Alzheimer disease. Alzheimer’s Dis. 
Assoc. Disord. 20, S69–74.
Takahashi, R. H., Almeida, C. G., Kearney, 
P. F., Yu, F., Lin, M. T., Milner, T. A., and 
Gouras, G. K. (2004). Oligomerization 
of Alzheimer’s beta-amyloid within 
processes and synapses of cultured 
neurons and brain. J. Neurosci. 24, 
3592–3599.
Takahashi, R. H., Capetillo-Zarate, E., 
Lin, M. T., Milner, T. A., and Gouras, 
G. K. (2008). Co-occurrence of 
Alzheimer’s disease beta-amyloid 
and tau pathologies at synapses. 
Neurobiol. Aging 31. doi: 10.1016/j.
neurobiolaging.2008.07.021.
Lin, M. T., and Beal, M. F. (2006). 
Alzheimer’s APP mangles mitochon-
dria. Nat. Med. 12, 1241–1243.
Lord, A., Englund, H., Soderberg, L., 
Tucker, S., Clausen, F., Hillered, L., 
Gordon, M., Morgan, D., Lannfelt, 
L., Pettersson, F. E., and Nilsson, L. N. 
(2009). Amyloid-beta protoﬁ  bril levels 
correlate with spatial learning in Arctic 
Alzheimer’s disease transgenic mice. 
FEBS J. 276, 995–1006.
Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, 
P. A., Sturchler-Pierrat, C., Staufenbiel, 
M., Mautino, J., Vigo, F. S., Sommer, 
B., and Yankner, B. A. (2000). Amyloid 
beta interacts with the amyloid precur-
sor protein: a potential toxic mecha-
nism in Alzheimer’s disease. Nat. 
Neurosci. 3, 460–464.
Mackenzie, I. R., and Miller, L. A. (1994). 
Senile plaques in temporal lobe epi-
lepsy. Acta Neuropathol. 87, 504–510.
Meyer-Luehmann, M., Mielke, M., Spires-
Jones, T. L., Stoothoff, W., Jones, P., 
Bacskai, B. J., and Hyman, B. T. (2009). 
A reporter of local dendritic transloca-
tion shows plaque- related loss of neu-
ral system function in APP-transgenic 
mice. J. Neurosci. 29, 12636–12640.
Mori, C., Spooner, E. T., Wisniewsk, K. 
E., Wisniewski, T. M., Yamaguch, 
H., Saido, T. C., Tolan, D. R., Selkoe, 
D. J., and Lemere, C. A. (2002). 
Intraneuronal Abeta42 accumulation 
in Down syndrome brain. Amyloid 9, 
88–102.
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, 
D. H., and LaFerla, F. M. (2004). Abeta 
immunotherapy leads to clearance of 
early, but not late, hyperphosphor-
ylated tau aggregates via the protea-
some. Neuron 43, 321–332.
Oddo, S., Caccamo, A., Shepherd, J. D., 
Murphy, M. P., Golde, T. E., Kayed, R., 
Metherate, R., Mattson, M. P., Akbari, 
Y., and LaFerla, F. M. (2003). Triple-
transgenic model of Alzheimer’s 
disease with plaques and tangles: 
intracellular Abeta and synaptic dys-
function. Neuron 39, 409–421.
Oddo, S., Caccamo, A., Smith, I. F., Green, 
K. N., and LaFerla, F. M. (2006). A 
dynamic relationship between intra-
cellular and extracellular pools of 
Abeta. Am. J. Pathol. 168, 184–194.
Palop, J. J., Chin, J., Roberson, E. D., Wang, 
J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, 
K. O., Yu, G. Q., Kreitzer, A., Finkbeiner, 
S., Noebels, J. L., and Mucke, L. (2007). 
Aberrant excitatory neuronal activity 
and compensatory remodeling of 
inhibitory hippocampal circuits in 
mouse models of Alzheimer’s disease. 
Neuron 55, 697–711.
Perestenko, P. V., and Henley, J. M. (2003). 
Characterization of the   intracellular 
transport of GluR1 and GluR2 
alpha-amino-3-hydroxy-5-methyl-4-
plaques in Down syndrome. Arch. 
Pathol. Lab Med. 125, 489–492.
Hamos, J. E., DeGennaro, L. J., and 
Drachman, D. A. (1989). Synaptic 
loss in Alzheimer’s disease and other 
dementias. Neurology 39, 355–361.
Hsieh, H., Boehm, J., Sato, C., Iwatsubo, 
T., Tomita, T., Sisodia, S., and Malinow, 
R. (2006). AMPAR removal underlies 
Abeta-induced synaptic depression 
and dendritic spine loss. Neuron 52, 
831–843.
Iwata, N., Takaki, Y., Fukami, S., Tsubuki, 
S., and Saido, T. C. (2002). Region-
speciﬁ  c reduction of A beta-degrading 
endopeptidase, neprilysin, in mouse 
hippocampus upon aging. J. Neurosci. 
Res. 70, 493–500.
Kamenetz, F., Tomita, T., Hsieh, H., 
Seabrook, G., Borchelt, D., Iwatsubo, 
T., Sisodia, S., and Malinow, R. (2003). 
APP processing and synaptic function. 
Neuron 37, 925–937.
Kandimalla, K. K., Scott, O. G., Fulzele, 
S., Davidson, M. W., and Poduslo, J. F. 
(2009). Mechanism of neuronal versus 
endothelial cell uptake of Alzheimer’s 
disease amyloid beta protein. PLoS 
One 4, e4627. DOI:10.1371/journal.
pone.0004627.
Kang, J. E., Lim, M. M., Bateman, R. J., Lee, 
J. J., Smyth, L. P., Cirrito, J. R., Fujiki, 
N., Nishino, S., and Holtzman, D. M. 
(2009). Amyloid-beta dynamics are 
regulated by orexin and the sleep-wake 
cycle. Science 326, 1005–1007.
Kang, J. S., Tian, J. H., Pan, P. Y., Zald, P., Li, 
C., Deng, C., and Sheng, Z. H. (2008). 
Docking of axonal mitochondria by 
syntaphilin controls their mobility and 
affects short-term facilitation. Cell 132, 
137–148.
Knobloch, M., Konietzko, U., Krebs, D. C., 
and Nitsch, R. M. (2007). Intracellular 
Abeta and cognitive deﬁ  cits precede 
beta-amyloid deposition in transgenic 
arcAbeta mice. Neurobiol. Aging 28, 
1297–1306.
LaFerla, F. M., Green, K. N., and Oddo, S. 
(2007). Intracellular amyloid-beta in 
Alzheimer’s disease. Nat. Rev. Neurosci. 
8, 499–509.
Lazarov, O., Robinson, J., Tang, Y. P., 
Hairston, I. S., Korade-Mirnics, Z., 
Lee, V. M., Hersh, L. B., Sapolsky, 
R. M., Mirnics, K., and Sisodia, S. S. 
(2005). Environmental enrichment 
reduces Abeta levels and amyloid 
deposition in transgenic mice. Cell 
120, 701–713.
Li, F., Calingasan, N. Y., Yu, F., Mauck, 
W. M., Toidze, M., Almeida, C. G., 
Takahashi, R. H., Carlson, G. A., Flint 
Beal, M., Lin, M. T., and Gouras, G. 
K. (2004). Increased plaque burden in 
brains of APP mutant MnSOD hetero-
zygous knockout mice. J. Neurochem. 
89, 1308–1312.
accumulating amyloid can undergo 
lysis to form amyloid plaques in 
Alzheimer’s disease. Histopathology 
38, 120–134.
DeKosky, S. T., and Scheff, S. W. (1990). 
Synapse loss in frontal cortex biopsies 
in Alzheimer’s disease: correlation 
with cognitive severity. Ann. Neurol. 
27, 457–464.
Deshpande, A., Kawai, H., Metherate, R., 
Glabe, C. G., and Busciglio, J. (2009). 
A role for synaptic zinc in activity-
dependent Abeta oligomer formation 
and accumulation at excitatory syn-
apses. J. Neurosci. 29, 4004–4015.
Dong, H., Martin, M. V., Chambers, S., 
and Csernansky, J. G. (2007). Spatial 
relationship between synapse loss and 
beta-amyloid deposition in Tg2576 
mice. J. Comp. Neurol. 500, 311–321.
Echeverria, V., Ducatenzeiler, A., Dowd, 
E., Janne, J., Grant, S. M., Szyf, M., 
Wandosell, F., Avila, J., Grimm, H., 
Dunnett, S. B., Hartmann, T., Alhonen, 
L., and Cuello, A. C. (2004). Altered 
mitogen-activated protein kinase 
signaling, tau hyperphosphorylation 
and mild spatial learning dysfunc-
tion in transgenic rats expressing the 
beta-amyloid peptide intracellularly 
in hippocampal and cortical neurons. 
Neuroscience 129, 583–592.
Fagan, A. M., Head, D., Shah, A. R., Marcus, 
D., Mintun, M., Morris, J. C., and 
Holtzman, D. M. (2009). Decreased 
cerebrospinal fluid Abeta(42) cor-
relates with brain atrophy in cogni-
tively normal elderly. Ann. Neurol. 
65, 176–183.
Fukami, S., Watanabe, K., Iwata, N., 
Haraoka, J., Lu, B., Gerard, N. P., 
Gerard, C., Fraser, P., Westaway, D., 
St George-Hyslop, P., and Saido, T. C. 
(2002). Abeta-degrading endopepti-
dase, neprilysin, in mouse brain: syn-
aptic and axonal localization inversely 
correlating with Abeta pathology. 
Neurosci. Res. 43, 39–56.
Garcia-Osta, A., and Alberini, C. M. 
(2009). Amyloid beta mediates 
memory formation. Learn. Mem. 16, 
267–272.
Gouras, G. K., Almeida, C. G., and 
Takahashi, R. H. (2005). Intraneuronal 
Abeta accumulation and origin 
of plaques in Alzheimer’s disease. 
Neurobiol. Aging 26, 1235–1244.
Gouras, G. K., Tsai, J., Naslund, J., Vincent, 
B., Edgar, M., Checler, F., Greenﬁ  eld, 
J. P., Haroutunian, V., Buxbaum, J. 
D., Xu, H., Greengard, P., and Relkin, 
N. R. (2000). Intraneuronal Abeta42 
accumulation in human brain. Am. J. 
Pathol. 156, 15–20.
Gyure, K. A., Durham, R., Stewart, W. 
F., Smialek, J. E., and Troncoso, J. C. 
(2001). Intraneuronal abeta-amyloid 
precedes development of amyloid Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 13  |  5
Tampellini and Gouras  Aβ and synapses in AD
Conflict of Interest Statement: The 
authors declare that they have no com-
mercial or financial relationship that 
could be construed as a potential conﬂ  ict 
of interest.
Received: 08 January 2010; paper pending 
published: 16 February 2010; accepted: 12 
March 2010; published online: 21 May 
2010.
Citation: Tampellini D and Gouras GK 
(2010) Synapses, synaptic activity and 
intraneuronal Aβ in Alzheimer’s disease. 
Front. Ag. Neurosci. 2:13. doi: 10.3389/
fnagi.2010.00013
Copyright © 2010 Tampellini and Gouras. This 
is an open-access article subject to an exclusive 
license agreement between the authors and the 
Frontiers Research Foundation, which permits 
unrestricted use, distribution, and reproduc-
tion in any medium, provided the original 
authors and source are credited.
Trinchese, F., Liu, S., Ninan, I., Puzzo, D., 
Jacob, J. P., and Arancio, O. (2004b). 
Cell cultures from animal models of 
Alzheimer’s disease as a tool for faster 
screening and testing of drug efﬁ  cacy. 
J. Mol. Neurosci. 24, 15–21.
Wirths, O., Multhaup, G., Czech, C., 
Blanchard, V., Moussaoui, S., Tremp, G., 
Pradier, L., Beyreuther, K., and Bayer, T. 
A. (2001). Intraneuronal Abeta accu-
mulation precedes plaque formation 
in beta-amyloid precursor protein and 
presenilin-1 double-transgenic mice. 
Neurosci. Lett. 306, 116–120.
Yang, A. J., Chandswangbhuvana, D., 
Shu, T., Henschen, A., and Glabe, C. 
G. (1999). Intracellular accumula-
tion of insoluble, newly synthesized 
abetan-42 in amyloid precursor 
  protein-transfected cells that have 
been treated with Abeta1-42. J. Biol. 
Chem. 274, 20650–20656.
promotes APP transport to synapses, 
and protects against Abeta-related 
synaptic alterations. J. Neurosci. 29, 
9704–9713.
Terry, R. D., Masliah, E., Salmon, D. 
P., Butters, N., DeTeresa, R., Hill, 
R., Hansen, L. A., and Katzman, R. 
(1991). Physical basis of cognitive 
alterations in Alzheimer’s disease: 
synapse loss is the major correlate of 
cognitive impairment. Ann. Neurol. 
30, 572–580.
Thinakaran, G., and Koo, E. H. (2008). 
Amyloid precursor protein trafﬁ  ck-
ing, processing, and function. J. Biol. 
Chem. 283, 29615–29619.
Trinchese, F., Liu, S., Battaglia, F., Walter, 
S., Mathews, P. M., and Arancio, O. 
(2004a). Progressive age-related devel-
opment of Alzheimer-like pathology 
in APP/PS1 mice. Ann. Neurol. 55, 
801–814.
Takahashi, R. H., Milner, T. A., Li, F., Nam, 
E. E., Edgar, M. A., Yamaguchi, H., 
Beal, M. F., Xu, H., Greengard, P., and 
Gouras, G. K. (2002). Intraneuronal 
Alzheimer abeta42 accumulates in 
multivesicular bodies and is associ-
ated with synaptic pathology. Am. J. 
Pathol. 161, 1869–1879.
Tampellini, D., Magrane, J., Takahashi, 
R. H., Li, F., Lin, M. T., Almeida, 
C. G., and Gouras, G. K. (2007). 
Internalized antibodies to the Abeta 
domain of APP reduce neuronal 
Abeta and protect against synap-
tic alterations. J. Biol. Chem. 282, 
18895–18906.
Tampellini, D., Rahman, N., Gallo, 
E. F., Huang, Z., Dumont, M., 
Capetillo-Zarate, E., Ma, T., Zheng, 
R., Lu, B., Nanus, D. M., Lin, M. T., 
and Gouras, G. K. (2009). Synaptic 
activity reduces intraneuronal Abeta, 